Drugs / ATC-CD20Bi
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00521261 | Oct 2007 → Jul 2008 | lymphoma | Barbara Ann Karmanos Cancer Institute | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATC-CD20Bi | “Patients receive ATC-CD20Bi IV on days 40, 70, 100, 130, and 160 after SCT.” NCT00521261 ↗ |
| Modality | Cell therapy | “anti-CD3 X anti-CD20 bispecific antibody (CD20Bi)-armed activated T cells (ATC)” NCT00521261 ↗ |
| Route | Intravenous | “Patients receive ATC-CD20Bi IV on days 40, 70, 100, 130, and 160 after SCT.” NCT00521261 ↗ |